Dear Colleague,
GTC's 10th Anti-infectives Partnering and Deal-Making
Conference, taking place on July 8-9, 2013 in Boston, MA, will
contribute to the on-going battle against the ever-changing infectious threats
by having experts with direct experiences in the field discuss a wide variety of
topics on infectious diseases. The agenda also allows time for networking and
opportunities to interface with speakers and fellow delegates in a collegial
setting. Previous GTC conferences have been catalytic to several successful
partnerships and in 2013 we expect this trend to continue.
GTC’s Anti-Infectives
Partnering & Deal Making is an infectious disease partnering and business
development conference that gives global biotechnology and pharmaceutical
companies an opportunity to network with high-level executives from top pharma
and various biotech/pharmaceutical companies, explore potential collaborations,
and learn about relevant anti-infective issues and deals that will affect the
industry. This event also provides a unique venue for attendees to learn about
the anti-infective business development trends, the infectious disease markets,
and novel technologies that shape up the industry.
Sessions of the conference include:
- Regulatory Guidance and Overcoming Challenges in Anti-Infectives
Development
- Recent Advances in Anti-Infectives
- Neglected Infectious Diseases
- Old Drug, New Drugs
- Novel Diagnostics Against Drug Resistance
- Government Collaborations and Non-dilutive Funding
- Multi Drug Resistant Gram Negative Infections
There will also be several interactive Panel Discussions on:
- Current Trends and Future in Anti-infectives Development
- Regulatory Guidance and Overcoming Challenges in Anti-infectives
Development
- Licensing vs Co-development Partnerships
- Investment Opportunities with Venture Capitalists
- Finding the Middle Ground in Partnerships with Big Pharma and Govt.
The conference will run parallel with 2 other information-packed
conference as part of the
Infectious Diseases World Summit 2013:
11th Vaccines Research & Development: All Things Considered
2nd Influenza Research & Development
We look forward to seeing you at the conference!
Best
regards,
The 2013 Advisory Committee
|
|
MEDIA PARTNERS |
|
 |
|
|